Agenus Inc (AGEN)

$5.40 +0.04 (0.75%)
Market Cap 146.96M
Revenue (ttm) 103.46M
Net Income (ttm) -227.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 3.55
Profit Margin -219.61%
Debt to Equity Ratio -0.10
Volume 347,800
Avg Vol 1,384,360
Day's Range N/A - N/A
Shares Out 27.42M
Stochastic %K 5%
Beta 1.62
Analysts Sell
Price Target $11.50

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
2_logs_higher
2_logs_higher Aug. 4 at 10:58 PM
$AGEN $INCY Tell new ceo at INCY to buy Agenus with conviction. www.fiercepharma.com/pharma/incytes-new-ceo-pledges-fresh-look-business-outlines-dealmaking-strategy
1 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 9:30 PM
$AGEN maybe garo should do another appearance on the stone zone..lol!
0 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 9:26 PM
$AGEN anybody still here that bought into garos best token scam?
0 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 5:49 PM
$AGEN $INKT pump it and dump it baby!
0 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 4:58 PM
$INKT $AGEN all the way back to $7, how low does agenus go !
0 · Reply
docBNM
docBNM Aug. 4 at 4:35 PM
$AGEN volume has dried up. We need a legit catalyst. I kinda thought August would be our month. LFG
1 · Reply
Biotechguy21
Biotechguy21 Aug. 4 at 4:14 PM
$AGEN wrong again. this team is killing it 👇👇👇🤡🤡🤡😂😂😂😂
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Aug. 4 at 3:51 PM
$AGEN Pazdur is getting heat. Seriously FUCK that guy he has been gatekeeping cancer drugs off the market. Insanity. Pazdur is the hold up with agenus's progress.
2 · Reply
Biotechguy21
Biotechguy21 Aug. 4 at 2:43 PM
$AGEN tokens? or vouchers? 🤡🤡😂😂
0 · Reply
manny11419
manny11419 Aug. 4 at 2:11 PM
$AGEN Part 2 This trial has > 90% power to detect the alternative hypothesis while maintaining a one-sided significance level of not more than 0.10 using the exact binomial. The study will be monitored for early stopping in favor of the null hypothesis based on a Simon’s two stage design. In the first stage, 69 patients will be enrolled (Arm A:46 and Arm B:23). If at the end of the first stage, Arm A has either at least 18/42 (42.8%) of eligible patients responding or an ORR at least numerically equivalent to that for eligible patients in Arm B, then the trial will progress to the second stage. The primary endpoint will be met if there are 38/80 responders (ORR > 47.5%) in Arm A. Key secondary endpoints include landmark progression-free survival, treatment-free survival and rates of immune-related adverse events. Correlative studies will explore immune and molecular predictors of response and resistance to IO/IO in tumor and blood. Clinical trial information: NCT05928806.
1 · Reply
Latest News on AGEN
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Jul 31, 2025, 7:30 AM EDT - 4 days ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Jul 25, 2025, 12:46 PM EDT - 10 days ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jul 7, 2025, 8:55 AM EDT - 4 weeks ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 17, 2025, 7:30 AM EDT - 6 weeks ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 7 weeks ago

Agenus Announces Virtual Annual Shareholders Meeting

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 4, 2025, 2:38 PM EDT - 2 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 30, 2025, 7:30 AM EDT - 2 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 23, 2025, 3:09 PM EDT - 2 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025, 10:40 AM EDT - 2 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 2:46 PM EDT - 3 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 3 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025, 7:20 AM EDT - 3 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 29, 2025, 7:30 AM EDT - 3 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 28, 2025, 3:30 PM EDT - 3 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 25, 2025, 1:05 PM EDT - 3 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Apr 23, 2025, 12:05 PM EDT - 3 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 25, 2025, 4:40 PM EDT - 4 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 19, 2025, 7:30 AM EDT - 4 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 5 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Mar 11, 2025, 7:30 AM EDT - 5 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 26, 2025, 4:48 PM EST - 5 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 2:30 PM EST - 5 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 25, 2025, 8:26 AM EST - 5 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 24, 2025, 8:33 AM EST - 5 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 5 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 6 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 29, 2025, 12:37 PM EST - 6 months ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Jan 22, 2025, 2:48 PM EST - 6 months ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 18, 2024, 7:30 AM EST - 8 months ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Dec 5, 2024, 7:30 AM EST - 8 months ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 27, 2024, 8:15 AM EST - 8 months ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:41 AM EST - 9 months ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Nov 12, 2024, 7:00 AM EST - 9 months ago

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Nov 7, 2024, 10:00 AM EST - 9 months ago

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Nov 5, 2024, 7:30 AM EST - 9 months ago

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 9 months ago

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 9 months ago

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Oct 30, 2024, 6:30 PM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

2_logs_higher
2_logs_higher Aug. 4 at 10:58 PM
$AGEN $INCY Tell new ceo at INCY to buy Agenus with conviction. www.fiercepharma.com/pharma/incytes-new-ceo-pledges-fresh-look-business-outlines-dealmaking-strategy
1 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 9:30 PM
$AGEN maybe garo should do another appearance on the stone zone..lol!
0 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 9:26 PM
$AGEN anybody still here that bought into garos best token scam?
0 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 5:49 PM
$AGEN $INKT pump it and dump it baby!
0 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 4:58 PM
$INKT $AGEN all the way back to $7, how low does agenus go !
0 · Reply
docBNM
docBNM Aug. 4 at 4:35 PM
$AGEN volume has dried up. We need a legit catalyst. I kinda thought August would be our month. LFG
1 · Reply
Biotechguy21
Biotechguy21 Aug. 4 at 4:14 PM
$AGEN wrong again. this team is killing it 👇👇👇🤡🤡🤡😂😂😂😂
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Aug. 4 at 3:51 PM
$AGEN Pazdur is getting heat. Seriously FUCK that guy he has been gatekeeping cancer drugs off the market. Insanity. Pazdur is the hold up with agenus's progress.
2 · Reply
Biotechguy21
Biotechguy21 Aug. 4 at 2:43 PM
$AGEN tokens? or vouchers? 🤡🤡😂😂
0 · Reply
manny11419
manny11419 Aug. 4 at 2:11 PM
$AGEN Part 2 This trial has > 90% power to detect the alternative hypothesis while maintaining a one-sided significance level of not more than 0.10 using the exact binomial. The study will be monitored for early stopping in favor of the null hypothesis based on a Simon’s two stage design. In the first stage, 69 patients will be enrolled (Arm A:46 and Arm B:23). If at the end of the first stage, Arm A has either at least 18/42 (42.8%) of eligible patients responding or an ORR at least numerically equivalent to that for eligible patients in Arm B, then the trial will progress to the second stage. The primary endpoint will be met if there are 38/80 responders (ORR > 47.5%) in Arm A. Key secondary endpoints include landmark progression-free survival, treatment-free survival and rates of immune-related adverse events. Correlative studies will explore immune and molecular predictors of response and resistance to IO/IO in tumor and blood. Clinical trial information: NCT05928806.
1 · Reply
manny11419
manny11419 Aug. 4 at 2:10 PM
$AGEN Would appreciate if any trial design expert can interpret this trial for us. Part 1 Methods: ARCITECT is a phase II, multicenter study evaluating the efficacy and safety of Bot/Bal relative to Nivo/Ipi. Patients with mccRCC ( favorable, intermediate, or poor risk), no prior systemic therapy (including adjuvant or neoadjuvant), and at least one measurable lesion as defined by RECIST 1.1 are eligible for enrollment. 120 patients will be randomized in a 2:1 fashion to Arm A (Bot/Bal induction followed by Bal maintenance) or Arm B (Nivo/Ipi induction followed by Nivo maintenance) each for a maximum of 2 years. Stratification factors include IMDC risk groups and sarcomatoid histology. The primary endpoint is overall response rate (ORR) per RECIST 1.1. We hypothesize that Bot/Bal will lead to a superior ORR (55%) relative to Nivo/Ipi (40%). This trial has > 90% power to detect the alternative hypothesis while maintaining a one-side
2 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 1:14 PM
$AGEN xtra xtra read all about it...vouchers here...vouchers here!
0 · Reply
neversurrender2024
neversurrender2024 Aug. 4 at 12:59 PM
$AGEN good morning stuck holders....the strategic plan is to dilute investors into oblivion! one week from today the dilution number are out...
0 · Reply
robbiekuss1
robbiekuss1 Aug. 4 at 8:41 AM
$AGEN Important week ahead. Watch it BioGuy21
0 · Reply
dugger
dugger Aug. 4 at 3:21 AM
$AGEN Announcement Mon or Tue?
1 · Reply
Biotechguy21
Biotechguy21 Aug. 4 at 3:08 AM
$AGEN and running g out of cash 👇👇👇🤡🤡🤡😂😂😂😂😂
0 · Reply
docBNM
docBNM Aug. 2 at 3:44 PM
$AGEN time is of the essence …
0 · Reply
isEEu28
isEEu28 Aug. 1 at 4:03 PM
$OPEN $QS $LCID $PLUG $AGEN … my top watches going into the weekend/ early next week 👀
0 · Reply
neversurrender2024
neversurrender2024 Aug. 1 at 3:10 PM
$AGEN the next tesla...lol! more like the next enron!
0 · Reply
BillyBobBleach
BillyBobBleach Aug. 1 at 1:42 PM
$AGEN I guess a PR and a contractual deadline mean nothing to these clowns. I wonder if it was just a PR stunt to pump the SP. Clearly Zydus isn’t impressed with Agenus or they wouldn’t have taken the full 60 days. I don’t want to hear about tariffs….tariffs actually favor this deal.
2 · Reply
neversurrender2024
neversurrender2024 Aug. 1 at 1:02 PM
$AGEN good morning stuck holders ...more bad news. drug pricing! how low will she go....
0 · Reply
dugger
dugger Aug. 1 at 11:48 AM
This is probably responsible for the delay in earnings conference call: $AGEN As of yet, August 1st. 2025, the Zynext Ventures–Agenus deal is still undergoing regulatory review, with no public confirmation yet of final clearance. The acquisition—Zynext’s $16 million investment for a 5.9% stake in Agenus—is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and CFIUS (Committee on Foreign Investment in the United States). The original timeline allowed for completion within 60 days of the June 3 announcement, with a possible 30-day extension. Our government at work...
1 · Reply